CDK4 and neoplasm: Further evaluation of CDK4 protein levels in a larger panel of cell lines, and ultimately in tumour samples from melanoma patients treated with PD0332991, would be required to definitively determine the clinical relevance of CDK4 protein as a predictive biomarker for PD0332991 response.